Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.
Gerhardt Attard, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea Juliana Gomes, Karina Costa Maia Vianna, Hong Luo, Heather H. Cheng, Won Bae Kim, Carlos Federico Varela, Daneen Schaeffer, Shiva Dibaj, Susan Li, Fei Shen, Suneel Mundle, David Olmos, Kim N., Dana E. Rathkopf (2025). Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.. , 43(17_suppl), DOI: https://doi.org/10.1200/jco.2025.43.17_suppl.lba5006.
Article211 days agoAMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).
Dana E. Rathkopf, Kim N., David Olmos, Heather H. Cheng, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Vinny Hayreh, Angela Lopez‐Gitlitz, Peter Francis, Gerhardt Attard (2021). AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).. , 39(6_suppl), DOI: https://doi.org/10.1200/jco.2021.39.6_suppl.tps176.
Article211 days agoNiraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Gerhardt Attard, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea Juliana Gomes, Karina Vianna, Hong Luo, Geoffrey Gotto, Heather H. Cheng, Won Bae Kim, Carly R. Varela, Daneen Schaeffer, K. Krämer, Susan Li, Benoît Baron, Fei Shen, Suneel Mundle, Sharon McCarthy, David Olmos, Kim N., Dana E. Rathkopf (2025). Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. , 31(12), DOI: https://doi.org/10.1038/s41591-025-03961-8.
Article13 hours ago